Does PCOS mean I cannot get pregnant?

No. PCOS is the most common cause of anovulatory infertility, but most women with PCOS can conceive — either naturally or with assistance. Lifestyle changes, particularly modest weight loss and improved insulin sensitivity, often restore ovulation on their own. When medication is needed, letrozole successfully induces ovulation in the majority of women with PCOS and produces higher live birth rates than clomiphene. IVF is available for cases where simpler treatments have not worked, and fertility outcomes with appropriate management are generally very good.

Is PCOS caused by being overweight?

Not exactly. Obesity significantly worsens PCOS by amplifying insulin resistance and androgen production, but PCOS also affects lean women — approximately 20–30% of those diagnosed have a normal BMI. The relationship is bidirectional: PCOS promotes weight gain through insulin resistance and hormonal effects, and excess weight in turn worsens PCOS. Weight management is an important part of treatment, but PCOS is not simply caused by being overweight, and lean women with PCOS still require full evaluation and management.

Does PCOS go away after menopause?

PCOS does not disappear at menopause, though its presentation changes. Reproductive and androgen symptoms often become less prominent as ovarian function declines. However, the metabolic features — insulin resistance, dyslipidaemia, and elevated cardiovascular risk — persist and can worsen after menopause. Women with PCOS require ongoing monitoring of metabolic and cardiovascular risk factors throughout and beyond the menopausal transition, not just during their reproductive years.

Is PCOS linked to diabetes?

Yes. Women with PCOS have a 3–7 times higher risk of developing type 2 diabetes compared to women without PCOS, primarily because insulin resistance is central to the condition. The risk increases further with age, obesity, and a family history of diabetes. All women with PCOS should be screened regularly for prediabetes and type 2 diabetes using fasting glucose and HbA1c, and lifestyle interventions to improve insulin sensitivity should be a core part of long-term management.

Is PCOS testing and treatment covered under provincial health plans in Canada?

Diagnostic testing — including hormone panels and pelvic ultrasound — is covered under provincial health insurance (such as OHIP in Ontario or MSP in British Columbia) when ordered by a physician or nurse practitioner. Prescription medications commonly used for PCOS, including metformin and combined oral contraceptives, are listed on most provincial formularies, though coverage varies by province and plan. Letrozole for ovulation induction is covered in some provinces but may require special authorization. Supplements such as inositol are not covered. Patients should confirm specific coverage with their provincial drug benefit program or private insurer.

Polycystic ovary syndrome — Glossary

What it is

Polycystic ovary syndrome (PCOS) is the most common hormonal condition affecting women of reproductive age, estimated to affect 8–13% of women worldwide — and up to 20% when broader diagnostic criteria are applied. Also called PCOS or, in updated Mayo Clinic terminology, polyendocrine metabolic ovarian syndrome (PMOS), it is a complex hormonal and metabolic syndrome defined by a cluster of three features: irregular or absent ovulation, elevated androgens (male-type hormones), and in many cases, polycystic ovarian morphology visible on ultrasound.

Despite its name, PCOS is not primarily a condition of ovarian cysts. The "cysts" are actually immature follicles that arrest before ovulation — a downstream effect of the underlying hormonal disruption. PCOS is a syndrome, meaning it spans a wide spectrum of presentations. Some people are affected mainly by reproductive symptoms such as irregular periods and difficulty conceiving; others experience androgen-driven features like excess facial hair, acne, and scalp thinning; many have significant metabolic dysfunction including insulin resistance and elevated cardiovascular risk.

PCOS is the leading cause of anovulatory infertility worldwide. Over the long term it is associated with substantially increased risks of type 2 diabetes, metabolic syndrome, endometrial cancer (from chronic anovulation), and cardiovascular disease. It is a lifelong condition — its features evolve with age but do not resolve at menopause. In Canada, PCOS is diagnosed and managed across primary care, gynaecology, and endocrinology; testing through LifeLabs or Dynacare typically includes a hormone panel and fasting metabolic markers.

Causes and mechanism

PCOS is multifactorial, involving disrupted hormone signalling, insulin resistance, and genetic predisposition. Three mechanisms are central:

Disrupted LH/FSH ratio. The pituitary produces excess luteinizing hormone (LH) relative to follicle-stimulating hormone (FSH). This overstimulates ovarian theca cells to produce androgens — testosterone and androstenedione — without sufficient FSH to drive follicle maturation through to ovulation.
Insulin resistance. Present in approximately 70% of women with PCOS, insulin resistance causes the pancreas to overproduce insulin. Elevated insulin directly stimulates ovarian androgen production and suppresses sex hormone-binding globulin (SHBG), increasing the amount of free testosterone circulating in the blood. Insulin resistance is the primary driver of PCOS's metabolic complications.
Androgen excess. Elevated androgens disrupt normal follicle development, causing multiple small follicles to stall at an immature stage rather than maturing to ovulation — producing the characteristic polycystic ovarian appearance on ultrasound.

Contributing factors include strong family history (having a first-degree relative with PCOS meaningfully raises risk), obesity (which amplifies insulin resistance and peripheral androgen production via aromatase), and possibly in utero androgen exposure. Emerging research also points to gut microbiome alterations as a contributing factor, though this evidence is still early.

Symptoms and diagnosis

PCOS symptoms vary considerably between individuals. Diagnosis uses the Rotterdam criteria, which require at least 2 of the following 3 features:

Feature	What it means clinically
Oligo- or anovulation	Cycles longer than 35 days, fewer than 8 periods per year, or absent periods
Hyperandrogenism	Clinical (hirsutism, acne, alopecia) or biochemical (elevated testosterone/DHEA-S)
Polycystic ovarian morphology	≥20 follicles per ovary or increased ovarian volume on ultrasound

Androgen-driven symptoms include hirsutism (coarse hair on the face, chin, chest, or abdomen), jawline acne, androgenetic alopecia (crown thinning), and oily skin. Metabolic symptoms include central weight gain, fatigue, difficulty losing weight, and acanthosis nigricans (dark, velvety skin in body folds). Depression and anxiety are significantly more common in people with PCOS than in the general population.

Diagnostic workup typically includes a menstrual history, hormone panel (total and free testosterone, DHEA-S, SHBG, LH, FSH, prolactin, TSH), fasting insulin and glucose, and pelvic ultrasound. Other causes — thyroid dysfunction, hyperprolactinaemia, congenital adrenal hyperplasia, and androgen-secreting tumours — must be excluded before confirming a PCOS diagnosis.

Treatment options

Management is tailored to the individual's primary concerns. There is no single treatment for PCOS; most people require a combination of approaches.

Lifestyle modification is foundational for all presentations. Weight loss of even 5% in people with overweight significantly reduces androgen levels, improves cycle regularity, and lowers metabolic risk. Regular aerobic and resistance exercise improves insulin sensitivity. A low-glycaemic, anti-inflammatory dietary pattern reduces insulin and androgen levels.

For cycle regulation and endometrial protection: Combined oral contraceptive pills reduce androgen levels, regulate cycles, and protect the endometrium from hyperplasia caused by chronic anovulation. Cyclical progestogen is an alternative for those who cannot take combined pills.

For androgen symptoms: Spironolactone is an anti-androgen effective for hirsutism and hormonal acne. Combined oral contraceptives with anti-androgenic progestogens are also used.

For insulin resistance: Metformin reduces insulin resistance, lowers androgens, and often restores more regular cycles. Myo-inositol and D-chiro-inositol have emerging evidence as natural insulin sensitizers in PCOS, though they are not yet part of standard Canadian guidelines.

For fertility: Letrozole is the current first-line agent for ovulation induction in PCOS and produces higher live birth rates than clomiphene citrate. Clomiphene remains an option. FSH injections are used when oral agents fail. IVF is available for cases where ovulation induction has not achieved pregnancy.

When to see a clinician in Canada

See a clinician if you have cycles longer than 35 days or fewer than 8 periods per year, persistent acne or excess facial/body hair, scalp hair thinning, difficulty conceiving, or a family history of PCOS or type 2 diabetes. PCOS is significantly underdiagnosed — many people are told irregular cycles are normal or that their symptoms are unrelated. A full hormonal and metabolic evaluation can confirm the diagnosis and identify the right management approach for your specific presentation.

In Canada, family physicians, gynaecologists, and endocrinologists all manage PCOS. Virtual care platforms — including Felix, Maple, Cleo, Phoenix, and others — can facilitate initial assessment and prescription management for those with limited local access. Routine metabolic monitoring (fasting glucose, HbA1c, lipids) should continue throughout life, not just during the reproductive years.

Limitations and open questions

Research is still emerging on several aspects of PCOS. The role of the gut microbiome in PCOS pathophysiology is an active area of investigation but has not yet translated into clinical recommendations. The optimal long-term management of PCOS after menopause — particularly cardiovascular risk reduction — is not well defined in current guidelines. Health Canada has not issued specific guidance on inositol supplements for PCOS, and the evidence base for their use, while promising, remains limited compared to established pharmacological options. The 2023 international PCOS guideline represents the most current consensus, but questions remain about the best diagnostic thresholds for adolescents, the management of lean PCOS, and the long-term safety of various ovulation induction protocols. Psychological comorbidities in PCOS are well documented but remain undertreated in most clinical settings.

Polycystic ovary syndrome